FY2024 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Zacks Research reduced their FY2024 earnings per share (EPS) estimates for Bruker in a note issued to investors on Monday, December 23rd. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $2.39 per share for the year, down from their prior forecast of $2.40. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2024 earnings at $0.74 EPS, Q1 2025 earnings at $0.52 EPS, Q2 2025 earnings at $0.58 EPS, Q3 2025 earnings at $0.71 EPS, FY2025 earnings at $2.76 EPS, Q3 2026 earnings at $0.81 EPS and FY2026 earnings at $3.41 EPS.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. Bruker’s revenue was up 16.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.74 EPS.

BRKR has been the topic of a number of other reports. Wells Fargo & Company reduced their target price on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Bank of America lifted their target price on Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a report on Friday, December 13th. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. UBS Group began coverage on Bruker in a research report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price target on the stock. Finally, The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a research report on Thursday, December 5th. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $74.45.

Bruker Trading Up 1.5 %

NASDAQ BRKR opened at $58.25 on Wednesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66. The firm has a market cap of $8.83 billion, a price-to-earnings ratio of 28.00, a PEG ratio of 4.00 and a beta of 1.18. The firm has a 50 day simple moving average of $57.73 and a 200-day simple moving average of $62.30. Bruker has a one year low of $48.07 and a one year high of $94.86.

Institutional Trading of Bruker

A number of large investors have recently made changes to their positions in BRKR. True Wealth Design LLC lifted its stake in Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after buying an additional 510 shares during the last quarter. UMB Bank n.a. raised its position in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd acquired a new stake in Bruker during the 2nd quarter worth $52,000. GAMMA Investing LLC grew its position in Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after purchasing an additional 388 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in Bruker during the 3rd quarter worth $73,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bruker

In other news, CEO Frank H. Laukien bought 100,000 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were acquired at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 28.30% of the company’s stock.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were issued a dividend of $0.05 per share. The ex-dividend date was Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.34%. Bruker’s payout ratio is currently 9.62%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.